Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2005-06-17 (20 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: AUXERRE (89000), Yonne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DU PONT : revenue, balance sheet and financial ratios
SELARL PHARMACIE DU PONT is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in AUXERRE (89000),
this company of category PME
shows in 2023 a revenue of 1.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DU PONT (SIREN 482879475)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
1 648 181 €
N/C
N/C
N/C
N/C
N/C
Net income
103 067 €
88 412 €
97 303 €
173 909 €
131 002 €
120 587 €
51 666 €
67 989 €
EBITDA
N/C
N/C
129 363 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
5.9%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DU PONT generates positive net income of 103 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 68 k€ -> 103 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
103 067 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
4.1%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
84.607%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DU PONT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
77.819
62.561
46.174
34.249
24.191
16.098
8.608
4.1
Financial autonomy
50.205
55.301
59.476
66.327
70.829
76.331
80.768
84.607
Repayment capacity
None
None
None
None
None
1.933
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
5.906%
None%
None%
Sector positioning
Debt ratio
4.12025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Excellent
In 2025, the debt ratio of SELARL PHARMACIE DU PONT (4.10) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
84.61%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent+10 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE DU PONT (84.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
1.93 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SELARL PHARMACIE DU PONT (1.93) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 216.09. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
216.089
Liquidity indicators evolution SELARL PHARMACIE DU PONT
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
159.083
155.898
160.673
204.055
224.177
230.214
212.452
216.089
Interest coverage
None
None
None
None
None
2.594
None
None
Sector positioning
Liquidity ratio
216.092025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good
In 2025, the liquidity ratio of SELARL PHARMACIE DU PONT (216.09) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
2.59x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE DU PONT (2.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE DU PONT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
154 484 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
26
0
0
Customer payment term (days)
0
0
0
0
0
4
0
0
Supplier payment term (days)
0
0
0
0
0
42
0
0
Positioning of SELARL PHARMACIE DU PONT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DU PONT is estimated at
1 637 231 €
(range 1 111 033€ - 2 569 041€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1111k€1637k€2569k€
1 637 231 €Range: 1 111 033€ - 2 569 041€
NAF 5 année 2025
Valuation method used
Net Income Multiple
103 067 €
×
15.9x
=1 637 232 €
Range: 1 111 033€ - 2 569 042€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DU PONT with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DU PONT
What is the revenue of SELARL PHARMACIE DU PONT ?
The revenue of SELARL PHARMACIE DU PONT in 2023 is 1.6 M€.
Is SELARL PHARMACIE DU PONT profitable?
Yes, SELARL PHARMACIE DU PONT generated a net profit of 103 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DU PONT ?
The headquarters of SELARL PHARMACIE DU PONT is located in AUXERRE (89000), in the department Yonne.
Where to find the tax return of SELARL PHARMACIE DU PONT ?
The tax return of SELARL PHARMACIE DU PONT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DU PONT operate?
SELARL PHARMACIE DU PONT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart